Sinopharm Group Co Ltd
XMUN:X2S
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
S
|
Sinopharm Group Co Ltd
XMUN:X2S
|
CN |
|
Kuaishou Technology
F:5Y0
|
CN |
|
P
|
Progressive Corp
F:PGV
|
US |
|
H
|
Hochtief AG
F:HOT
|
DE |
|
S
|
Swatch Group AG
DUS:UHR
|
CH |
|
H
|
HSBC Holdings PLC
XMUN:HBC1
|
UK |
|
C
|
Capital One Financial Corp
F:CFX
|
US |
|
A
|
Allegion PLC
SWB:60A
|
IE |
|
Horizon Gold Ltd
F:HO0
|
AU |
|
B
|
Brunello Cucinelli SpA
XMUN:8BU
|
IT |
|
R
|
REN Redes Energeticas Nacionais SGPS SA
XMUN:RN4
|
PT |
Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What you see on other sites is mostly sourced from sell-side analysts.
What is X2S's stock price target?
Price Target
2.418
EUR
According to Wall Street analysts, the average 1-year price target for 
X2S is 2.418 EUR with a low forecast of 1.929 EUR and a high forecast of 3.181 EUR.
What is the Revenue forecast for Sinopharm Group Co Ltd?
Projected CAGR
4%
Over the last 13 years, the compound annual growth rate for Revenue has been 12%. The projected CAGR for the next 3 years is 4%.
What is the Gross Profit forecast for Sinopharm Group Co Ltd?
Projected CAGR
9%
Over the last 13 years, the compound annual growth rate for Gross Profit has been 11%. The projected CAGR for the next 3 years is 9%.
What is the Operating Income forecast for Sinopharm Group Co Ltd?
Projected CAGR
7%
Over the last 13 years, the compound annual growth rate for Operating Income has been 10%. The projected CAGR for the next 3 years is 7%.
What is the Pre-Tax Income forecast for Sinopharm Group Co Ltd?
Projected CAGR
7%
Over the last 13 years, the compound annual growth rate for Pre-Tax Income has been 11%. The projected CAGR for the next 3 years is 7%.
What is the Net Income forecast for Sinopharm Group Co Ltd?
Projected CAGR
7%
Over the last 13 years, the compound annual growth rate for Net Income has been 10%. The projected CAGR for the next 3 years is 7%.